| Margins | Margins expected to contract in FY27 before recovery in FY28. |
|---|---|
| Demand visibility | Visibility in oncology and GLP-1 (semaglutide) launches in emerging markets. |
| Management confidence | Confident in long-term diversification strategy despite immediate cyclical dip. |
Growth
FY26 revenue dropped to ₹4,375.9cr from ₹4,784cr; PAT fell to ₹1,418.5cr from ₹1,883.4cr.
Outlook
FY27 guidance: ₹3,400-3,500cr revenue and ₹700-750cr PAT. Expecting 15-25% CAGR growth from FY28 onwards.
Risks
Revlimid revenue decline, Middle East war impacting freight costs, and high competitive intensity in US generics.
Last quarter's promises, checked
Delivered
- Guided H1 PAT ₹1,000cr → delivered ₹1,000cr (= BEAT)
- Guided H2 PAT ₹270-300cr → delivered ₹418.5cr (= BEAT)
- Guided FY26 PAT ₹1,275-1,300cr → delivered ₹1,418.5cr (= BEAT)
Partly delivered
- Targeted Semaglutide India launch March/April 2026 → Launched in Q4 (= PARTIAL)
Missed
- Guided FY26 Revenue ~₹4,600cr → delivered ₹4,375.9cr (= MISS)
Earnings Call filed with BSE, NSE: NATCOPHARM. Summary written with AI assistance from the document.
Natco Pharma Ltd: key numbers
- Share price
- ₹839.30
- Market cap
- ₹15,033 Cr
- Revenue (annual)
- ₹4,078 Cr
- Net profit (annual)
- ₹1,418 Cr
- P/E (TTM)
- 13.1×Sector 50.4×
- Promoter holding
- 49.42%+0.00% QoQ
- FII holding
- 16.99%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Natco Pharma Ltd
All →Natco Pharma Fund Raise of ₹1,279 Cr
Natco Pharma's board has approved a Rights Issue to raise ₹1,279.36 Crore. The company will issue 17,058,082 equity shares at ₹750 each in a 2:21 ratio.
- Value
- ₹1,279 Cr
Natco Pharma Capital Structure Change
Natco Pharma's board approved a Rights Issue of 1,70,58,082 shares aggregating to ₹1,279.36 Crore. The issue is priced at ₹750 per share with a 2:21 ratio.
- Value
- ₹1,279 Cr
Natco Pharma Board Meeting Date
Natco Pharma will hold a board meeting on 25th September 2026 to finalise terms for its previously approved rights issue, including pricing and record date.
Natco Pharma Capital Structure Change
Natco Pharma has received in-principle approval from BSE and NSE for its upcoming Rights Issue of fully paid-up equity shares.
Natco Pharma Capital Structure Change
Natco Pharma proposes a Rights Issue of equity shares aggregating up to ₹1,300 Crore. The company has filed the Draft Letter of Offer for this capital raise.
- Value
- ₹1,300 Cr
Natco Pharma Fund Raise of ₹1,300 Cr
Natco Pharma board approved a rights issue of up to ₹1,300 crore face value ₹2 equity shares. The demerger scheme will be revised post-completion of the raise.
- Value
- ₹1,300 Cr